Synact in Media

December 10, 2021

SynAct discusses AP1189 with Sedermera

December 10, 2021

MedWatch: Synact Pharma vil intensivere partner-drøftelser

December 7, 2021

SynAct discusses AP1189 Phase 2a results with Direkt

December 3, 2021

BioStock Studio: SynAct Pharma comments on the promising study results in RA

November 30, 2021

SynAct Pharma’s AP1189 meets primary endpoint – Nordic Life Science – the leading Nordic life science news service

November 30, 2021

Scrip: SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

November 11, 2021

BioStock: SynAct Pharma’s CSO and CMO comment on clinical development

July 28, 2021

Nordic Life Science News: SynAct Pharma announces positive additional trial data

June 30, 2021

DagensPS: Lungfunktion vid Covid-19 förbättras med svensk läkemedelskandidat

June 17, 2021

Healthcare Direkt v. 24 l Synact Pharma om kommande fas 2-resultat

February 5, 2021

Finwire – En tydlig utvecklingsplan för AP1189 stärker förhandlingspositionen

November 11, 2020

SynAct Pharma mentioned in the Rheumatoid Arthritis (RA) – Pipeline Insight, 2020

September 23, 2020

DI (Nyhetsbyrån Direkt): Synact Pharma startar fas 2-studie med covid-patienter

September 22, 2020

BIOSTOCK: SynAct Pharma sees potential in several viral diseases

September 22, 2020

BIOSTOCK: SynAct Pharma ser potential inom flera virussjukdomar

July 3, 2020

Cision Promoted: Emission teckningsoptioner ska driva två projekt genom fas II

June 30, 2020

Aktiespararna: Intensiv höst med sikte på utlicensiering i horisonten

June 2, 2020

BIOSTOCK: SynAct närmar sig studiestart efter myndighetsgodkännande

May 12, 2020

Redeye: Interview with CEO Jeppe Øvlesen and CSO Thomas Jonassen (video call)

May 6, 2020

BIOSTOCK: SynAct comments on positive Phase II data

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19

April 2, 2020

BIOSTOCK: SynAct Pharma om Covid-19-satsningen (in Swedish)

April 1, 2020

Synact Pharma in spotlightanalysen (in Swedish)

April 1, 2020

Medwatch: Synact rekrutterer fortsat til forsøg trods pandemi (in Danish)

March 31, 2020

Life Science Sweden: Vill dämpa lunginflammationen vid covid-19 (in Swedish)

March 31, 2020

Medwatch: Synact Pharma vil teste hovedkandidat som tillægsbehandling til coronasyge patienter (in Danish)

March 31, 2020

Dagens Industri: Spotlight-bolag planerar preparattester på coronapatienter (in Swedish)

December 6, 2019

Medwatch: Synact Pharma kommer i mål med aktieemission – overtegnet med 295 pct (in Danish)

November 12, 2019

Medwatch: Synact får grønt lys til forsøg i Sverige (in Danish)

October 21, 2019

Medwatch: Biotekselskab vil starte nyt forsøg med hovedaktiv og udsteder aktier for millioner (in Danish)

June 28, 2019

Medwatch: Biotekchef lander ny bestyrelsespost efter hjemtur til Danmark (in Danish)

April 1, 2019

Medwatch: Synact ready for phase II with arthritis candidate: “An important milestone for the company”

April 1, 2019

Medwatch: Synact er klar til fase 2 med gigthåb: “En stor milepæl for selskabet” (in Danish)

February 11, 2019

Medwatch: Synact skal rejse 14 mio kr til nyt forsøg med hovedkandidat (in Danish)

August 21, 2018

Medwatch: Synact Pharmas hovedkandidat viser lovende takter mod sjælden nyresygdom (in Danish)

May 12, 2018

Medwatch: Synact Pharma fordobler svensk kapitalrejsning (in Danish)